Greece Struggles to...
Health Care: Drugs
Oncolytics Biotechnology Incorporated (ONCY: NASDAQ)
$5.15 -0.04 | -0.87%
02/09/12 - 03:59 PM ET
63.46K / 76.50K
Vol / Avg. Vol:5.20 / 5.20
Open / Prev. Close:5.05 - 5.20
Today's Range:3.15 - 6.69
52 Wk Range:33.21%
Performance YTD:TheStreet Rating:
Portfolios with ONCY
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- UserASCO 2010
- Userrussbow98 Portfolio 1
- Userwallacee Portfolio 1
- UserASCO 2009 Nymph's Watch List.
- Userdoom-n-gloom
- Userutopian_holdings
- Userjohndboyle Portfolio 1
- UserDenverbill1027 Portfolio 1
- Usernickelsworth1 Portfolio 1
Latest ONCY Headlines from TheStreet
- 8 Stocks Under $10 Moving Higher 02.02.12 | 02:02 pm
- BIO CEO Conference Live Blog 02.14.11 | 02:02 pm
- Amgen Makes Bet on Viral Skin Cancer Killer 01.26.11 | 10:01 am
- Biotech's Brighter Corners 12.08.10 | 12:12 pm
- Columbia Laboratories, Cardionet: Early Volume Plays 06.01.10 | 09:06 am
- Poniard, Netlist: Early Volume Plays 11.18.09 | 08:11 am
- The Pisani Paradox
09.28.09 | 11:09 am - Wednesday's Small-Cap Winners & Losers 04.09.08 | 03:04 pm
- Wednesday's Health Winners & Losers 10.24.07 | 03:10 pm
- Monday's Health Winners & Losers 10.01.07 | 02:10 pm
Press Releases for ONCY
- Oncolytics Biotech® Inc. Announces Phase 2 Clinical Trial Of REOLYSIN® In Combination With Gemcitabine In Pancreatic Cancer Reaches Primary Endpoint - PR Newswire 12.02.11 | 07:12 am
- Oncolytics Biotech® Inc. Announces Start Of Conformity Testing With SAFC® - PR Newswire 11.21.11 | 07:11 am
- Oncolytics Biotech® Inc. Announces Positive Results Of U.S. Phase 2 Clinical Trial Investigating REOLYSIN® In Combination With Paclitaxel And Carboplatin In Head And Neck Cancers - PR Newswire 11.14.11 | 07:11 am
- Oncolytics Biotech® Inc. Collaborators To Present Positive Phase 2 REOLYSIN Clinical Data In Pancreatic Cancer At The AACR-NCI-EORTC Molecular Targets And Cancer Therapeutics Conference - PR Newswire 11.14.11 | 07:11 am
- Oncolytics Biotech® Inc. To Host Conference Call To Discuss Clinical Data Being Presented At The AACR-NCI-EORTC Molecular Targets And Cancer Therapeutics Conference - PR Newswire 11.11.11 | 04:11 pm
- Oncolytics Biotech Announces Appointments To Senior Management Team - PR Newswire 11.10.11 | 07:11 am
- Media Advisory - Oncolytics Biotech® Inc. To Present At The JMP Securities Healthcare Conference - PR Newswire 09.22.11 | 07:09 am
- Media Advisory - Oncolytics Biotech® Inc. To Present At The Wedbush 2011 Life Sciences Management Access Conference - PR Newswire 08.11.11 | 07:08 am
- Oncolytics Biotech® Inc. To Present At 31st Canaccord Genuity Growth Conference - PR Newswire 08.03.11 | 07:08 am
- Oncolytics Biotech® Inc. Announces Publication Of Preclinical Research On Synergistic Combination Of Chemotherapy With Oncolytic Virotherapy - PR Newswire 08.02.11 | 07:08 am
Partner Headlines for ONCY
- Baker's Dozen Trying To Beat The Odds In Pancreatic Cancer - Seeking Alpha 10.25.11 | 08:10 am
- Company News for May 18, 2011 - Corporate Summary - Zacks 05.18.11 | 10:05 am
- Oncolytics Pushes Its Pipeline Further - Seeking Alpha 12.02.10 | 09:12 am
- Predictions for Biotech Data Heading to ASCO - Seeking Alpha 06.02.10 | 03:06 am
- Oncolytics Ready for Final Clinical Step With Reolysin - Seeking Alpha 05.20.10 | 10:05 am
